MedTrace Logo

C1-inhibitor in Allergic ASThma Patients

NCT03051698 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 37

Last updated 2020-06-24

No results posted yet for this study

Summary

The purpose of this proof-of-concept study is to determine the effect of Intestinal Microbiota Depletion or Intravenous Administration of C1-inhibitor on Inflammation and Coagulation after Bronchial Instillation of House Dust Mite Allergen and Lipopolysaccharide in Allergic Asthma Patients

Conditions

Interventions

DRUG

C1-inhibitor

100 Unit/kg IV, one gift prior to broncho provocation.

OTHER

Saline

0.9% NaCl

DRUG

Antibiotics

vancomycin, ciprofloxacin, metronidazole

Sponsors & Collaborators

  • ZonMw: The Netherlands Organisation for Health Research and Development

    collaborator OTHER

  • Prothya Biosolutions

    collaborator INDUSTRY

  • T. van der Poll

    lead OTHER

Principal Investigators

  • Tom vd Poll, Prof, dr, MD · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-11-16
Primary Completion
2019-10-23
Completion
2019-10-23

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03051698 on ClinicalTrials.gov